TRVI · Healthcare · $2.0B
$14.32-0.69%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Among 463 Biotechnology peers
“트레비 테라퓨틱스는 만성 기침 치료제 'Haduvio'를 IPF(특발성 폐섬유증), 비IPF 간질성 폐질환, 난치성 만성 기침 등 세 가지 적응”
In the company's words · 2026 1분기 earnings call